{"nctId":"NCT00264797","briefTitle":"Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)","startDateStruct":{"date":"2006-02"},"conditions":["ADHD","Substance Abuse"],"count":303,"armGroups":[{"label":"Methylphenidate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Methylphenidate (OROS-MPH)"]},{"label":"Methylphenidate (Placebo)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Methylphenidate (OROS-MPH) - Placebo"]}],"interventions":[{"name":"Methylphenidate (OROS-MPH)","otherNames":[]},{"name":"Methylphenidate (OROS-MPH) - Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meet Diagnostic and Statistical Manual for Mental Disorders, 4th Edition (DSM-IV) diagnostic criteria for ADHD\n* Meet DSM-IV diagnostic criteria for at least one non-nicotine substance use disorder\n* Has a DSM-IV ADHD Symptom Checklist score â‰¥ 22 derived from the adolescent-completed checklist\n\nExclusion Criteria:\n\n* Serious medical illness\n* History of tic disorder\n* Pregnant or breastfeeding\n* Meet DSM-IV criteria for current or life-time psychotic disorder\n* Meet DSM-IV criteria for current or life-time bipolar disorder\n* Requires/or prescribed other concurrent psychotropic medication\n* Taking any medications that may produce interactions with OROS-MPH\n* Opiate dependence\n* Methamphetamine abuse or dependence\n* Suicidal risk\n* Enrolled in an inpatient, residential, day treatment, or outpatient substance abuse program within 28 days prior to signing consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"13 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"ADHD Severity","description":"DSM IV ADHD Rating Scale (ADHD-RS) adolescent informant, ascertained at baseline and weekly throughout the 16 week study. This scale is an 18-item symptom checklist of self-reported adolescent ADHD symptoms. Symptoms are scored as None (0), Mild (1), Moderate (2), and Severe (3), with a summary total of scores for the 18 symptoms. Possible scores range from 0 to 54, with higher scores indicating greater severity. Outcome is measured as the decrease in total severity score over time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.6","spread":"11.1"},{"groupId":"OG001","value":"-21.8","spread":"11.9"}]}]}]},{"type":"PRIMARY","title":"Substance Use","description":"The change in number of days of substance use from baseline to end of the trial. The number of days of non-tobacco drug/alcohol ascertained using standard timeline follow back (TLFB) procedures.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"0.8"},{"groupId":"OG001","value":"-5.2","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"OROS-MPH Abuse Liability","description":"Assessed by pill counts in conjunction with weekly review of subjects' medication diaries and self-reported medication compliance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":"18.7"},{"groupId":"OG001","value":"9.7","spread":"11.2"}]}]}]},{"type":"SECONDARY","title":"Substance Use Outcomes","description":"The mean number of negative urine drug screens (UDS).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"4.9"},{"groupId":"OG001","value":"2.8","spread":"4.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":151},"commonTop":["Headache","Abdominal Pain Upper","Nasopharyngitis","Pharyngolaryngeal Pain","Insomnia"]}}}